|1.||Nikiforov, Yuri E: 43 articles (12/2015 - 01/2002)|
|2.||Miyauchi, Akira: 41 articles (11/2015 - 01/2003)|
|3.||High, Katherine A: 33 articles (03/2015 - 04/2002)|
|4.||Ito, Yasuhiro: 32 articles (03/2015 - 01/2004)|
|5.||Santoro, Massimo: 32 articles (01/2014 - 01/2002)|
|6.||Herzog, Roland W: 28 articles (11/2015 - 04/2002)|
|7.||Xing, Mingzhao: 28 articles (04/2015 - 03/2004)|
|8.||Tuttle, R Michael: 27 articles (12/2015 - 06/2002)|
|9.||Kobayashi, Kaoru: 27 articles (01/2015 - 01/2004)|
|10.||Miya, Akihiro: 27 articles (03/2014 - 01/2004)|
|1.||Hemophilia B (Haemophilia B)
01/01/1993 - "This direct approach, which is based on computer-aided analysis of the whole coding, promoter and exon-flanking factor IX gene sequences, proved to be helpful for carrier detection and prenatal diagnosis in most hemophilia B families, including sporadic cases. "
10/01/2008 - "Investigation of factor IX (FIX) has benefited from excellent gene-deleted mouse models that recapitulate many of the features of human haemophilia B. "
10/01/2014 - "Hemophilia B management has improved considerably since the introduction of high-purity plasma-derived factor IX (pdFIX) products in the early 1990s. "
09/01/2013 - "The rapid clearance of factor IX (FIX) necessitates frequent intravenous administration to achieve effective prophylaxis for patients with hemophilia B. "
03/01/1992 - "The American Red Cross has developed an immunoaffinity chromatography method to purify human coagulation Factor IX to high levels of purity for therapeutic treatment of hemophilia B. "
|2.||Neoplasm Metastasis (Metastasis)
01/01/2012 - "It is possible that some PTC-SCC patients without distant metastasis who undergo locally curative surgery can survive for a prolonged period and adjuvant therapies can be effective for local and distant recurrences."
04/01/2013 - "High frequency recurrence, distant metastasis and treatment resistance can be found in cases of PTC so early diagnosis and treatment are critical for improved prognosis and better survival rates. "
05/01/2002 - "Average MMP-1 expression (mean relative intensity units+/-SE) was significantly greater among PTC (1.97+/-0.15; p=0.004) and FTC (2.2+/-0.25; p=0.006) compared to benign lesions (1.30+/-0.15); but there was no relationship between MMP-1 expression and invasion, metastasis, or recurrence. "
12/01/2000 - "In patients with RET/PTC chimeras, a statistically not significant tendency towards younger age, lower recurrence rate, and improved survival was observed, despite increased incidence of lymph node metastasis. "
01/01/2013 - "Both partial and comprehensive superior mediastinal dissections are effective and safe for the treatment of mediastinal metastasis of PTC if appropriately designed."
07/29/2015 - "Recently, photothermal therapy (PTT) that utilizes photothermal conversion (PTC) agents to ablate cancer under near-infrared (NIR) irradiation has attracted a growing amount of attention because of its excellent therapeutic efficacy and improved target selectivity. "
04/01/2015 - "Adjusting for age and baseline scores, participants receiving PTC had significantly improved depression and improved gynecologic and cancer-specific concerns at 4 months compared with UC participants (all P < .05); significant differences in gynecologic and cancer-specific concerns (P < .05) were sustained at 9 months. "
06/01/2009 - "Cases of PTC with many MGCs have a significantly greater likelihood of extrathyroidal extension and greater tumor size than cases with few/no MGCs. "
06/15/1991 - "Thereafter, however, the number of pTc detected was significantly greater in eyes bearing progressively growing AC tumors than in SC tumor-injected eyes. "
07/01/2005 - "PTC is superior to total vascular exclusion except in patients with tumors that are large and deep seated, hypervascular, and/or abutting the hepatic veins or vena cava and in patients with increased right-sided heart pressures."
|4.||Hemophilia A (Haemophilia)
07/01/1999 - "Since in most countries carrier detection is based on factor IX coagulant activity (FIX:C) assay, this study was designed to determine whether carriers' FIX:C values are dependent on the severity of haemophilia (mild, moderate or severe) or on the genetic anomaly in the family. "
08/10/1997 - "In the case of factor IX, we have produced a high-titer adenovirus vector capable of transducing gut epithelial cells resulting in synthesis of factor IX. The results of our in vitro studies indicate that gene transfer targeting gut epithelium as a new approach to hemophilia gene therapy is rational and merits in vivo studies in hemophilia animal models."
07/01/1995 - "Gene therapy is a potential treatment for hemophilia, wherein cells transduced with a normal factor IX gene could provide a continuous in vivo source of circulating factor IX. In this study, we examined the potential use of hematopoietic cells as a target for factor IX gene therapy. "
05/01/1953 - "[Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency]."
06/01/2015 - "In addition, recent advances in recombinant factor IX protein engineering have led some hemophilia treaters to reconsider the urgency of genetic cure. "
11/01/2015 - "Factor Consumption for Prophylaxis and Treatment of Bleeding: Recombinant Factor Ix Fc Fusion Protein Compared With Conventional Recombinant Factor Ix."
10/01/2015 - "Utilisation of this method has the potential to reduce the morbidity and mortality burden associated with post-PTC haemorrhage by preventing bleeding from the liver access tract."
01/01/2015 - "Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates."
05/01/2014 - "The use of coagulation factor IX concentrate to prevent anticipated bleeding, as primary or secondary prophylaxis, has become a common and recommended practice in children. "
08/01/2013 - "DPC was frequently presented in CHD patients undergoing PTC and associated with increasing minor/minimal bleeding and longer hospital stay. "
|1.||papillary Thyroid cancer
|2.||Factor VIII (Coagulation Factor VIII)
|4.||prothrombin complex concentrates (PPSB)
|6.||recombinant FVIIa (rFVIIa)
|7.||Proteins (Proteins, Gene)
|8.||Blood Coagulation Factors (Coagulation Factor)
|9.||Messenger RNA (mRNA)
|2.||Neck Dissection (Radical Neck Dissection)
|5.||Lymph Node Excision (Lymph Node Dissection)